18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model
Abstract Background Quantitative imaging can facilitate patient stratification in clinical trials. The hypoxia-activated prodrug evofosfamide recently failed a phase III trial in pancreatic cancer. However, the study did not attempt to select for patients with hypoxic tumors. We tested the ability o...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2018-06-01
|
| Series: | EJNMMI Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13550-018-0409-1 |